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Abstract
Background and objective: Reduced physical capacity (PC) and physical activity (PA) are common in COPD
patients and associated with poor outcome. However, they represent different aspects of physical functioning and
interventions do not affect them in the same manner. To address this, a new PC-PA quadrant concept was recently
generated to identify clinical characteristics of sub-groups of physical functioning. The objective of this study was to
I) proof the new concept and to verify their differentiating clinical characteristics, II) evaluate the consistency of the
concept over time, III) assess whether patients changed their quadrant affiliation over time, IV) and to test if
changes in quadrant affiliations are associated with changes in clinical characteristics.
Methods: In a longitudinal, prospective, non-interventional cohort with mild to very severe COPD patients, PC and
PA as well as respiratory variables, COPD-specific health status, comorbidities, survival, and exacerbations were
yearly assessed.
Results: Data from 283 patients were analysed at baseline. Mean (min/max) follow-up time was 2.4 (0.5/6.8) years.
The PC-PA quadrants could be characterized as follows: I) “can’t do, don’t do”: most severe and symptomatic,
several comorbidities II) “can do, don’t do”: severe but less symptomatic, several comorbidities III) “can’t do, do do”:
few patients, severe and symptomatic, less comorbidities IV) “can do, do do”: mildest and less symptomatic, less
comorbidities, lowest exacerbation frequency. Of the 172 patients with at least one follow-up, 58% patients never
changed their quadrant affiliation, while 17% declined either PC, PA or both, 11% improved their PC, PA or both,
and 14% showed improvement and decline in PC, PA or both during study period. None of the clinical
characteristics or their annual changes showed consistent significant and relevant differences between all individual
sub-groups.
Conclusion: Our findings suggest that there are no clinical characteristics allowing to distinguish between the PC-
PA quadrants and the concept seems not able to illustrate disease process. However, the already low PA but
preserved PC in the “can do, don’t do” quadrant raises the question if regularly assessment of PA in clinical practice
would be more sensitive to detect progressive deterioration of COPD compared to the commonly used PC.
Clinical trial registration: www.ClinicalTrials.gov, NCT01527773.
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Introduction
Chronic obstructive pulmonary disease (COPD) is fre-
quently accompanied by impaired physical capacity (PC)
and reduced daily physical activity (PA), both arising in
early disease stages [1]. Moreover, COPD patients are
less physically active than patients with other chronic
diseases, such as diabetes and rheumatoid arthritis [2].
Both, reduced ability to perform PA and PC, are known
to be associated with a poor outcome (impaired health
status, increased healthcare utilization) and are strong
predictors for all-cause mortality in COPD [3, 4]. PC
and PA represent two different aspects of physical func-
tioning. While PC represents the ability to perform ac-
tivity (a set of attributes), PA represents what people
really do during their daily routine (a complex behav-
iour) [5]. A recent longitudinal assessment of the courses
of PC and PA in COPD patients showed that PC
remained stable despite a substantial annual decrease in
PA [6]. This finding leads to our hypothesis, that the
longitudinal decline in PA cannot be explained by a con-
comitant reduction in exercise tolerance. Furthermore,
pulmonary rehabilitation shows a positive impact on PC
[7] but incongruent findings on PA improvement [8],
suggesting that an improvement in PC does not consist-
ently lead to an increase in PA. Further interventions
such as PA counselling or long-term oxygen therapy
showed variable effects on PA enhancement [9], but
studies comparing the effects of these interventions on
PC and PA are missing. This implies that interventions
may have to be individually tailored according to pa-
tients’ impairments in PC or PA, or both. According to
this new approach, Koolen et al. [10] recently developed
a PC-PA quadrant concept with PC (“can do”) and PA
(“do do”) plotted against axes. This PC-PA quadrant
concept identifies sub-groups of physical functioning
and comparison of different clinical characteristics may
provide an explanation for the discrepancies between PA
and PC in individual COPD patients.
To address the request of the authors to proof their
newly introduced PC-PA quadrant concept in another het-
erogeneous COPD cohort [10], we performed the analysis
accordingly and verified their findings regarding differences
in clinical characteristics in our cohort. Furthermore, add-
itional characteristics were compared among the quadrants.
Due to our longitudinal study design, we assessed I) the
consistency of the concept over time, II) whether patients
changed their quadrant affiliation over time, III) and if




In the prospective, non-interventional cohort project
“The Obstructive Pulmonary Disease Outcomes Cohort
Study (TOPDOCS)” patients with already diagnosed
mild to very severe COPD from seven pulmonary out-
patient clinics in Switzerland were included. Study
period was from October 2010 to December 2017 and
took place during outpatient visits or hospital stays. Pa-
tients were scheduled for initially three annual study
visits (some patients extended their participation up to
seven study visits). This analysis included data from 283
COPD patients out of the TOPDOCS cohort. Patients
aged between 40 and 75 years at inclusion with con-
firmed COPD according to Global Initiative for Chronic
Obstructive Lung Disease (GOLD)-guidelines [11] were
assessed for eligibility. Patients were excluded if they suf-
fered from mental or physical disability precluding in-
formed consent or compliance with the protocol. In case
of a COPD exacerbation, patients were included into the
study or called up for follow-up visits with a delay of at
least 6 weeks.
The study was conducted in accordance with the dec-
laration of Helsinki and all subjects gave written in-
formed consent to participate. The Ethics Committee of
the Canton of Zurich approved the study (EK-ZH-NR:




The 6-min walking distance (6MWD) was annually
assessed according to the American Thoracic Society
(ATS) guidelines [12]. The 6-min walking test (6MWT)
was performed on a 75m indoor track, and patients
were told to walk as far as possible within six minutes.
Oxygen supplementation was allowed if required. At
start and end of the test, peripheral oxygen saturation
was measured by oximeter (PC-60C Fingertip Oximeter,
Shanghai International Trading Corp. GmbH, Hamburg,
Germany). Percentage of predicted values of 6MWD was
calculated by reference equation of Enright et al. [13]
The minimal important difference (MID) for 6MWD in
COPD patients is estimated as 25 m [14].
Physical activity
The number of steps per day was measured by a validated,
triaxial accelerometer of a multisensory activity monitor
(SenseWear Pro™; Bodymedia Inc., Pittsburgh, PA, USA)
without a display (patient were blinded to the amount of
steps per day) [15]. The monitor was worn on the upper
left arm for 7 consecutive days once a year. The threshold
for valid data from the armband was set at 4 days with a
minimum of 22.5 h/day. Seasonality was considered in the
analysis. A change of 600 to 1100 steps per day is sup-
ported to be the MID in COPD patients [16].
Sievi et al. Respiratory Research           (2020) 21:27 Page 2 of 10
PC-PA quadrant concept
As described in the manuscript by Koolen and col-
leagues [10], the PC-PA quadrants were plotted as fol-
lows: “can’t do, don’t do” quadrant with low PC (6MWD
< 70% pred.) and low PA (number of steps per day <
5000 steps); “can do, don’t do” quadrant with preserved
PC (6MWD ≥70% pred.) but low PA (number of steps
per day < 5000 steps); “can’t do, do do” quadrant with
low PC (6MWD < 70% pred.) but preserved PA (number
of steps per day ≥5000 steps); “can do, do do” quadrant
with preserved PC (6MWD ≥70% pred.) and preserved
PA (number of steps per day ≥5000 steps).
To assess the longitudinal course of the PC-PA quad-
rant concept, patients were categorized into four “chan-
ging groups” according to their quadrant affiliations over
time. COPD patients who never changed their PC-PA
quadrant during study period were categorized as
“remainer”, “decliner” were patients who decreased their
physical functioning (decline in 6MWD < 70% pred.
and/or number of steps per day < 5000 steps) at least
once, “improver” increased their physical functioning
over time (increase in 6MWD ≥70% pred. and/or num-
ber of steps per day > 5000 steps) at least once, and
“waverer” included patients who increased and decreased
their physical functioning over time (increase and/or de-
crease in 6MWD and/or increase and/or decrease in
steps per day) at least once.
Respiratory variables
Standard pulmonary functional testing was performed
according to ATS/ERS guidelines [17, 18] to measure
forced expiratory volume in one second (FEV1), residual
volume to total lung capacity (RV/TLC) ratio, and dif-
fusing capacity of the lung for carbon monoxide (DLco).
Only values after bronchodilation were reported. Disease
severity was assessed by spirometric GOLD stages (stage
1–4) and COPD risk groups (risk score A-D) [19].
Blood gas analysis
Daytime arterial blood gas analysis was performed to as-
sess partial pressure of oxygen (PaO2), of carbon dioxide
(PaCO2) and oxygen saturation (SaO2) after 5 min of rest
(ABL 700 series blood gas analyzer, Radiometer,
Copenhagen). Measurement was performed native, ex-
cept few patients with consistent oxygen supplementa-
tion during blood gas analysis over all study visits.
COPD-specific health status
Severity of dyspnea was assessed by modified medical re-
search council (mMRC) scale [20], for which an MID is
not available due to its poor evaluative properties to de-
tect changes in dyspnea [21]. COPD Assessment Test
(CAT) was performed to measure the impact of COPD
symptoms on health status [22] with an estimated MID
of 2 points [23].
To assess states of anxiety and depression, the self-
administered Hospital Anxiety and Depression Scale
(HADS) was used. The questionnaire is composed of
two 7-item sub-scales (HADS-A for anxiety and HADS-
D for depression), sub-scores ranging from 0 to 21 with
higher scores indicating more severe distress. A score of
0 to 7 is suggested to be non-cases, 8 to 10 as possible
cases, and > 10 as probable cases of clinical anxiety or
depression, respectively [24]. A change of 1.5 points is
suggested to be the MID [25].
Comorbidities and survival
Comorbidities were annually assessed by review of the
documented medical history, conducting clinical inter-
views and clinical examinations. To classify comorbidi-
ties, the International Classification of Diseases-Tenth
Revision [26] was used. The number of comorbidities
was calculated by sum up the various diseases.
Last update in April 2019 was used to evaluate pa-
tients who died within or after the study period and to
assess survival time. Survival time was defined as time
from baseline visit to death or April 2019 in patients
who stayed alive. In patients who were lost of follow-up,
survival time was not calculated.
Exacerbation history
An acute exacerbation (AE) was defined as an increase
in patient’s dyspnea, cough and/or sputum with pre-
scription of antibiotics and/or corticosteroids. Severe ex-
acerbation was determined as hospital admission due to
AE. Annual acquisition of number of AEs during the
preceding year was performed and patients were catego-
rized into infrequent exacerbators (0–1 AE per year) and
frequent exacerbators (≥2 AEs per year) [27]. To get the
most accurate information on AE, patients reports were
compared with documents from the general practitioner,
pulmonologist and hospital.
Data analysis and statistics
All results are shown as mean values (standard deviation
(SD)) or median (25%/75% quartiles) unless otherwise
stated. Statistical analysis was performed with STATA
15.1 (StataCorp, Texas, USA).
Overall differences in PC-PA quadrants and in chan-
ging groups were compared by Kruskal-Wallis rank sum
test, due to the small sample size in some of the sub-
groups, and Chi square tests. For continuous variables,
non-parametric post-hoc tests were used to compare the
sub-groups among each other, p-values were Bonferroni
corrected. Post-hoc analysis of categorical variables were
assessed by Chi square test. For longitudinal data
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analysis, median annual change in each patients’ clinical
characteristics was calculated.




Of the 326 patients who agreed to take part, 283 COPD
patients (41% spirometric GOLD stage 1/2, 37% stage 3,
Fig. 1 Study flow
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23% stage 4) completed baseline visit and were included
in the analysis. Patients were asked to participate for at
least three study visits, with some patients extended up
to 7 study visits. During follow-up, 172 patients were
analysed at year 1, 124 at year 2, 44 at year 3, 16 at year
4, 4 at year 5 and 2 at year 6, respectively (Fig. 1). Rea-
sons for missing follow-up visits were withdrawal, not
able to participate anymore due to worsening health sta-
tus, lung transplantation, and death. Mean (min/max)
follow-up time was 2.4 (0.5/6.8) years with annual mea-
surements (median (quartiles) time between two visits
1.08 (1.01/1.20)). Comparison between patients who re-
ceived follow-up and patients who were lost for or failed
follow-up showed no differences in baseline PC and PA.
The median (quartiles) age was 63 (58/68) years, 65%
were male and 24% of the COPD patients were current
smokers. Mean (SD) PC was 79.4 (23.1)% of predicted
6MWD corresponding to 418 (125.7) meter. Median
(quartiles) PA was 4421 (2522/6863) steps per day. De-
tailed patient characteristics are presented in Table 1.
PC-PA quadrants
At baseline, 30% (85 patients) were categorized into the
“can’t do, don’t do” quadrant, 29% (81 patients) into the
“can do, don’t do” quadrant, 5% (13 patients) into the
“can’t do, do do” and 37% (104 patients) into the “can
do, do do” quadrant (Fig. 2).
Differences in clinical characteristics in PC-PA quadrants
Comparison of the PC-PA quadrants revealed significant
overall differences in various baseline values of clinical
characteristics, such as lung function, CAT score and
number of comorbidities (Table 2). In year 1, the overall
significant differences in clinical characteristics in the
PC-PA quadrants partly changed compared to baseline
(Additional file 1: Table S1). None of the clinical charac-
teristics showed significant and relevant differences be-
tween all of the individual quadrants (Table 3). The PC-
PA quadrants could be characterized as follows: I) “can’t
do, don’t do” quadrant: most severe and symptomatic
COPD patients, several comorbidities II) “can do, don’t
do” quadrant: severe but less symptomatic COPD pa-
tients, several comorbidities III) “can’t do, do do” quad-
rant: few patients, severe and symptomatic, less
comorbidities IV) “can do, do do” quadrant: mildest and
less symptomatic patients, less comorbidities, lowest ex-
acerbation frequency.
Median differences in CAT score between patients
with low PC and patients with preserved PC are remark-
ably above the MID of 2 points, despite lack of statistical
significance. Lung function impairment increases from
“can do, do do” quadrant to “can do, don’t do”/“can’t do,
do do” to “can’t do, don’t do” quadrant, with quite simi-
lar values between “can’t do, do do” and “can do, don’t
Table 1 Baseline characteristics
N = 283
Age, y 63 (58/68)
Male / Female, N 184 / 99
BMI, kg/m2 25.8 (22.4/28.7)
Waist / Hip ratio 0.97 (0.91/1.03)
Smoker / Former smoker, N (%) 67 (24) / 207
(73)
Pack years, N 40 (30/60)
mMRC score 2 (1/2)
CAT score 15 (11/20)
Anxiety score 4 (2/8)











FEV1, % pred. 44 (31/64)
RV/TLC, % 55.6 (11.7)
TLco, ml/mmHg/min 47 (35/68)
PaO2, kPa 9.04 (8.21/10.13)
PaCO2, kPa 5.03 (4.63/5.45)
SaO2, % 94.7 (93.0/96.0)
Number of comorbidities, N 3 (1/4)
Number of exacerbations in the previous year, N 1 (0/1)
Number of severe exacerbations in the previous year,
N
0 (0/0)
Frequent exacerbator, N (%) 68 (24)
Survival time, days 2094 (1420/
2483)
Retired person, N (%) 191 (68)
6MWD, m 418.3 (125.7)
6MWD, % pred. 79.4 (23.1)
SpO2 after 6MWT, % 90 (84/95)
Steps per day, N 4421 (2522/
6863)
BMI body mass index, mMRC modified medical research council, CAT COPD
assessment test, FEV1 forced expiratory volume in one second, RV/TLC residual
volume to total lung capacity ratio, TLco diffusing capacity of the lung for
carbon monoxide, PaO2 partial pressure of oxygen; PaCO2 partial pressure of
carbon dioxide; SaO2 oxygen saturation, 6MWD 6-min walking distance.
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do” quadrants. The median (95% CI) difference in
6MWD was above the MID with 35.2 (− 13.2/83.7) me-
ters in both groups with low PC, without statistical sig-
nificance. In the two groups with preserved PC, patients
in the “can do, don’t do” quadrant showed a relevant but
not significant median (95% CI) difference in 6MWD of
− 41.7 (− 67.8/− 15.6). Differences in steps per day were
rather small between low PA groups and between pre-
served PA groups, respectively. (Table 3).
Longitudinal properties of the PC-PA quadrant
After one year, the percentage of patients in the “can’t do,
don’t do” quadrant declined from 30 to 19% while the num-
ber of patients in the “can do, don’t do” quadrant increased
from 29 to 44%. The amount of patients in the remaining
two quadrants stayed quite stable (3 and 34%, respectively).
Of the 172 patients with at least one follow-up visit, 100
(58%) patients never changed their quadrant affiliation dur-
ing study period (remainer), while 29 patients (17%) wors-
ened either PC, PA or both (decliner), 20 patients (11%)
increased their PC, PA or both (improver), and 24 patients
(14%) showed increase and decrease in PC, PA or both
(waverer). Follow-up time was significantly longer in the
waverer group with median (quartiles) of 3.1 (2.2/4.0) years
compared to the remainer (2.1 (1.3/2.5) years) and decliner
(2.0 (1.1/3.1) years) (p < 0.001 and p= 0.011, respectively).
Of the patients in the “can’t do, don’t do” quadrant at
baseline, 51% remained in this quadrant while 24% were
improver and 24% waverer. In the “can do, don’t do”
quadrant, 63% were remainer, 7% decliner, 15% im-
prover and waverer each. 40% of the “can’t do, do do”
quadrant remained, while 20% were improver and 40%
waverer. The “can do, do do” quadrant at baseline yield
60% remainer, 35% decliner and 5% waverer.
Median yearly changes in most of the clinical characteris-
tics were comparable among the PC-PA quadrants. The
significant greater annual decline in number of steps per
day in the “can’t do, do do” quadrant compared to the “can
do, don’t do” quadrant did not show clinical relevance (me-
dian (quartiles) difference of − 449 (− 2728/1284) steps per
day) (p = 0.001). (Additional file 1: Table S2).
Differences in clinical characteristics in “changing groups”
None of the clinical parameters at baseline yield mean-
ingful differences between all of the four changing
groups (Additional file 1: Table S3). Improver showed a
significantly higher CAT score (median (95% CI) differ-
ence of 4.6 (1.3/7.9)) compared to remainer, and decliner
showed a significantly higher RV/TLC (median (95% CI)
difference of 7 (3/10)%) compared to remainer. 6MWD
and number of steps per day was lowest in the improver
group and highest in the decliner group. Furthermore,
median annual changes in clinical characteristics did not
differ relevantly between the changing groups despite a
relevant median (quartiles) difference in yearly change in
number of steps per day between decliners and improvers
of − 1120 (− 1722/− 557) steps (p < 0.001). (Table 4).
Discussion
This analysis applyed a recently introduced concept, taking
into account the differences in PC and PA for characterizing
COPD patients, in our heterogeneous cohort with longitu-
dinal assessments. Patients with low PC and PA presented
the worst health status, followed by patients with low PC but
preserved PA and patients with preserved PC but low PA.
Fig. 2 PC-PA quadrant at baseline. 6-min walking distance (x-axis) is potted against number of steps per day (y-axis)
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Preserved PC and PA was found in patients with the mildest
disease manifestations. Although 42% of the patients changed
their quadrant affiliation over time, none of the observed
clinical characteristics or their annual changes allowed to dis-
tinguish between patients who maintained, improved or de-
creased physical functioning over time.
Several studies demonstrated the deleterious impact of
reduced PC and PA on various outcomes in patients
with COPD [28–31]. Despite the effort to clarify the re-
lation of physical functioning and progress of COPD,
reasons for the divergent evolution between PC and PA
remain unknown. Why the positive effect of
Table 2 Comparison of clinical characteristics between quadrants at baseline
“Can’t do, don’t do”
N = 85
“Can do, don’t do”
N = 81
“Can’t do, do do”
N = 13




Age, y 64 (60/69) 64 (58/67) 56 (53/60)*† 64 (58/68)‡ 0.007
Male, N (%) 63 (74) 51 (63) 7 (54) 63 (61) 0.180
BMI, kg/m2 24.9 (21.1/28.1) 26.6 (22.8/29.4) 24.0 (22.6/25.8) 26.7 (22.6/29.2) 0.110
Waist/Hip ratio 0.98 (0.90/1.05) 0.98 (0.93/1.02) 0.93 (0.90/1.02) 0.96 (0.89/1.01) 0.250
Smoker, N (%) 11 (13) 25 (31)* 2 (15) 29 (28)* 0.026
mMRC score 3 (2/3) 1 (1/2)* 2 (1/3) 1 (1/2)* †‡ < 0.001
CAT score 18 (14/23) 14 (10/18)* 19 (13/22) 13 (8/19)* < 0.001
Anxiety score 5 (3/8) 3 (2/6) 7 (5/9) 4.5 (2.0/8.0) 0.080
Depression score 6 (4/8) 4 (2/6)* 5 (2/8) 3.5 (1.0/6.0)* < 0.001
GOLD, N (%) < 0.001
I 2 (2) 6 (7) 0 (0) 17 (16)*
II 11 (13) 27 (33)* 6 (46)* 48 (46)*
III 35 (41) 36 (44) 3 (23) 29 (28)†
IV 37 (44) 12 (15)* 4 (31) 10 (10)*‡
COPD Risk Group, N (%) < 0.001
A 4 (5) 16 (20)* 1 (8) 27 (26)*
B 68 (80) 54 (67) 10 (77) 60 (58)*
C 1 (1) 0 (0) 0 (0) 8 (8)*†
D 12 (14) 11 (14) 2 (15) 9 (9)
FEV1, % pred. 31 (25/43) 45 (34/65)* 41 (29/56) 58 (40.5/75.0)*
† < 0.001
RV/TLC, % 63 (57/68) 55 (45/65)* 55 (46/62) 52 (43/59)* < 0.001
TLco, % pred. 36 (28/45) 47 (36/64)* 43 (34/48) 63 (46/78)*†‡ < 0.001
PaO2, kPa 8.6 (7.6/9.5) 9.0 (8.4/10.1) 9.3 (8.5/9.6) 9.6 (8.8/10.5)* < 0.001
PaCO2, kPa 5.2 (4.7/5.7) 5.0 (4.5/5.3)* 5.0 (4.7/5.2) 4.9 (4.6/5.4) 0.047
SaO2, % 93.7 (91.2/95.3) 94.8 (93.3/96.0) 94.8 (94.5/96.0) 95.2 (93.7/96.5)* 0.007
Number of comorbidities, N 3 (2/5) 3 (2/5) 2 (1/2)*† 2 (1.0/3.5)*† < 0.001
Exacerbations in the previous year, N 1 (0/2) 0 (0/1) 1 (0/2) 0 (0/1)*‡ < 0.001
Severe exacerbations in the previous year, N 0 (0/1) 0 (0/0)* 0 (0/0) 0 (0/0)* 0.006
Frequent exacerbator, N (%) 28 (33) 20 (25) 6 (46) 14 (14)*‡ 0.004
Survival time, days (N = 214) 1550 (836/2268)a 2115 (1599/2394)b 2390 (1799/3019)c 2279 (1944/2839)d*† < 0.001
Retired person, N (%) 64 (76) 56 (70) 7 (54) 64 (62) 0.130
6MWD, m 300 (252/349) 450 (390/510)* 360 (300/375)† 495 (444/562)*‡ < 0.001
6MWD, % pred. 57 (47/65) 87 (77/95)* 61 (56/65)† 96 (95/107)*‡ < 0.001
SpO2 after 6MWT, % 87 (81/92) 90 (85/93)* 91 (87/95) 92 (87/95)* < 0.001
Steps per day, N 2388 (1329/3357) 3284 (2113/3864) 6590 (6007/9258)*† 7553 (5876/9819)*† < 0.001
Values are median (25%/75% quartiles) unless otherwise stated. * p < 0.05 vs “can’t do, don’t do”; † p < 0.05 vs “can do, don’t do”; ‡ p < 0.005 vs “can’t do, do do”.
aN = 69; bN = 62; cN = 8;dN = 75. BMI body mass index, mMRC modified medical research council, CAT COPD assessment test, FEV1 forced expiratory volume in one
second, RV/TLC residual volume to total lung capacity ratio, TLco diffusing capacity of the lung for carbon monoxide, PaO2 partial pressure of oxygen, PaCO2
partial pressure of carbon dioxide, SaO2 oxygen saturation, 6MWD 6-min walking distance
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Table 3 Differences in characteristics between individual quadrants at baseline
“Can’t do, don’t do”
vs “Can do, don’t do”
“Can’t do, don’t do”
vs “Can’t do, do do”
“Can’t do, don’t do”
vs “Can do, do do”
“Can do, don’t do”
vs “Can’t do, do do”
“Can do, don’t do”
vs “Can do, do do”
“Can’t do, do do”
vs “Can do, do do”
Age, y −1 (− 3/2) −8 (− 11/− 4)* 1 (− 3/1) −7 (− 10/− 4)* 0 (− 2/2) 7 (3/10)*
mMRC score, N − 1 (− 1/− 1)* 0 (− 1/0) − 1 (− 2/− 1)* 1 (0/1) 0 (− 1/0)* − 1 (− 2/0)*
CAT score, N − 4.3 (−6.1/− 2.4)* −0.14 (− 4.0/3.7) −4.6 (− 6.7/− 2.6)* 4.1 (0.6/7.6) −0.4 (− 2.4/1.6) −4.5 (− 8.9/− 0.1)
Depression score, N −2 (− 3/− 1)* −1 (− 3/2) − 2 (− 3/− 1)* 1 (−1/4) 0 (− 1/1) −1 (− 4/1)
FEV1, % pred. 13 (8/18)* 7 (−2/20) 23 (17/30)* −5 (−15/5) 9 (3/16)* 15 (6/25)
RV/TLC, % −7 (− 10.9/− 4.0)* −7 (− 14/0) − 11 (− 14/− 8)* 0 (−7/7) − 4 (− 8/0) − 4 (− 11/3)
TLco, % pred. 11 (6/17)* 6 (−2/15) 25 (18/31)* −5 (− 16/4) 12 (5/18)* 18.5 (8/28)*
Number of
comorbidities, N
−1 (− 1/0) −2 (− 2/− 1)* − 1 (− 2/− 1)* −1 (− 2/0)* −1 (− 1/0)* 1 (0/1)
Exacerbations in the
previous year, N
0 (−1/0) 0 (− 1/1) − 1 (− 1/0)* 1 (0/2) 0 (0/0) − 1 (− 2/0)*
Severe exacerbations
in the previous year, N
0 (0/0)* 0 (0/0) 0 (0/0)* 0 (0/0) 0 (0/0) 0 (0/0)
Survival time, days
(N = 214)
332 (49/698) 884 (328/1358) 732 (386/1075)* 461 (− 181/1069) 303 (62/568)* −84 (− 701/467)
6MWD, m 169.0(182.8/195.2)* 35.2 (−13.2/83.7) 210.7 (185.5/236.0)* − 133.8 (− 184.4/
83.2)*
41.7 (15.6/67.8) 175.5 (123.8/
227.2)*
6MWD, % pred. 32 (28/36)* 2 (− 3/8) 40 (36/44)* −29 (− 36/− 22)* 7 (3/12) 37 (31/44)*
SpO2 after 6MWT, % 2 (0/5)* 4 (1/7) −4 (2/7)* 1 (−1/4) 2 (4/1) 1 (−2/3)
Steps per day, N 692 (263/1108) 4770 (3716/6145)* 5193 (4657/5822)* 3990 (2916/5641)* 4477 (3939/5130)* 349 (− 627/1508)
Values are median (95% CI). *p-value < 0.05. mMRC modified medical research council, CAT COPD assessment test, FEV1 forced expiratory
volume in one second, RV/TLC residual volume to total lung capacity ratio, TLco diffusing capacity of the lung for carbon monoxide, 6MWD 6-
min walking distance, SaO2 oxygen saturation
Table 4 Comparison of median annual change in clinical characteristics between changing groups
Dependent variable Remainer N = 100 Decliner N = 29 Improver N = 20 Waverer N = 24 P-value
Median annual change BMI, kg/m2 −0.08 (− 0.75/0.66) − 0.03 (− 1.09/0.46) 0.01 (− 0.93/1.02) 0 (− 0.71/0.35) 0.740
Median annual change Waist/Hip ratio 0.01 (− 0.03/0.04) 0.01 (− 0.01/0.03) −0.01 (− 0.03/0.02) 0 (− 0.04/0.02) 0.094
Median annual change mMRC score 0 (0/1) 0 (0/1) 0 (− 1/0) 0 (0/1) 0.210
Median annual change CAT score 1 (−3/3) 2 (−2/4) −1 (− 5/3)† 1 (− 2/3)‡ 0.042
Median annual change Anxiety score 0 (− 2/1) 0 (− 1/1) 0 (− 2/1) 0 (− 1/2) 0.330
Median annual change Depression score 0 (−2/1) 0 (− 1/2) − 1 (− 2/0) † 0.5 (− 1.0/1.5) 0.045
Median annual change FEV1, % pred. 0 (−4/6) 0 (− 3/5) 3 (− 4/6) − 2 (− 6/1)* 0.046
Median annual change RV/TLC, % 0 (−5/5) 1 (− 5/5) 0 (− 3.0/2.5) 2.5 (− 2.5/6.0) 0.180
Median annual change TLco, % pred. −2 (− 6.7/4.0) − 3 (−9/2) 0 (− 6/6) − 1.0 (− 7.0/5.0) 0.400
Median annual change PaO2, kPa 0.1 (− 0.7/0.6) −0.21 (− 0.69/0.60) −0.20 (− 0.82/0.56) 0.08 (− 0.82/0.75) 0.840
Median annual change PaCO2, kPa 0 (− 0.31/0.23) 0.01 (− 0.27/0.20) −0.10 (− 0.29/0.14) 0.02 (− 0.17/0.42) 0.450
Median annual change SaO2, % 0 (− 1.1/1.2) 0.1 (− 1.5/1.0) −0.2 (− 1.5/1.0) 0 (− 1/1) 0.860
Median annual change Number of comorbidities 0 (0/0) 0 (0/1) 0 (0/1) 0 (0/0) 0.100
Median annual change Exacerbations in
the previous year, N
0 (− 1/0) 0 (− 1/1) 0 (−0.5/0.0) 0 (− 1/1) 0.850
Median annual change Severe exacerbations in the
previous year, N
0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0.810
Median annual change 6MWD, m 0 (− 30/30) −25 (− 60.0/28.7) 11 (− 18/57.5)† 0 (−75/35) 0.019
Median annual change 6MWD, % pred. 1.5 (− 3.0/10.0) 0 (−11/7) 9.5 (−2/20) 1 (− 14/14)‡ 0.005
Median annual change SpO2 after 6MWT, % 0 (−3/3) −1 (− 3/2) 0 (− 3/2) −1 (− 5/4) 0.540
Median annual change Steps per day, N − 298 (− 1418/566) − 1202 (− 2926/− 348)* − 192 (− 1393/1809)† − 761 (− 1870/665) < 0.001
Values are median (25%/75% quartiles). *p < 0.05 vs “remainer”; †p < 0.05 vs “worsener”; ‡p < 0.005 vs “improver”
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enhancements in PC, e.g. with pulmonary rehabilita-
tions, cannot always be transferred into enhanced PA is
a matter of current debate and research [32]. Further-
more, it remains to be defined if PA modifying interven-
tions, such as PA counselling, also enhances PC for long
term. A previous study by our team revealed that the
significant decrease in daily PA over time is not accom-
panied by a decrease in PC [6]. Consistent with these
findings, Koolen et al. [10] developed a new concept in
which PC and PA were divided into decreased and pre-
served. This PC-PA quadrant should enable the identifi-
cation of physical functioning sub-groups with different
clinical characteristics and might be useful in optimizing
personalized medicine in COPD patients. Following the
call to prove the new PC-PA quadrant concept, we ap-
plied the concept to our COPD cohort and investigated
if the PC-PA quadrant is applicable for dynamic
changes, assessed by longitudinal observations. Compar-
able to Koolen and colleagues [10], patients in the “can’t
do, don’t do” quadrant showed the highest disease bur-
den and patients in the “can do, do do” quadrant the
mildest COPD. However, none of the assessed clinical
characteristics allowed to distinguish between all of the
individual quadrants. Several of the differentiating char-
acteristics found by Koolen et al. [10], such as BMI and
sex, could not be confirmed by our study. Moreover,
some of the distinguishing characteristics found to be
significant in the baseline assessment were not main-
tained significant in the following year. The largest mis-
match was found in the “can do, don’t do” patients.
Koolen et al. [10] reported the smallest prevalence in
these patients and described them as “lazy”, with the
highest BMI and low exacerbation history. Our data sug-
gested that these patients show a comparable severity of
COPD with the “can’t do, do do” patients, but with
slightly lower symptoms and a higher PC. We thus
hypothesize that the already severe respiratory impair-
ment did not translate into a low PC yet, but will lead to
an impairment in PC with a delay in time. This finding
could also deliver an explanation why the annual de-
crease in PA is not accompanied by a decrease in PC [6],
leading to the assumption that PC may decrease with
delay while PA impairment goes in line with disease
worsening. To address this, longitudinal studies are
needed in which early disease stages are monitored and
the onset of PA impairment will be compared with the
onset of PC impairment. Furthermore, this raises the
question if regular assessment of PA in clinical practice
would be more sensitive to detect progressive deterior-
ation of COPD compared to the commonly used PC.
The PC-PA quadrant concept was not able to project
the dynamic course of the disease. Almost half of the pa-
tients changed their PC-PA quadrant over time but
changes in quadrant affiliation were not connected to
clinical characteristics or their annual changes. We
therefore assume that detailed characterization of the
four PC-PA quadrants would not be adequate. However,
further studies are needed to confirm whether patients
in the “can do, don’t do” quadrant show severe disease
burden and if these patients would be more responsive
for PA enhancement after pulmonary rehabilitations.
The current study has some limitations. Patients with
pulmonary rehabilitation within 3 months prior to the
baseline evaluation were not included at this time point.
However, we cannot exclude that a small number of se-
vere patients underwent pulmonary rehabilitation during
the study period, potentially increased the group of wa-
verers. Furthermore, the number of patients in the “can’t
do, do do” quadrant is quite small but seems to repre-
sent the real-world distribution of COPD patients.
Conclusion
In conclusion, we found no clinical characteristics to dis-
tinguish significantly and clinically meaningful between
the PC-PA quadrants. Furthermore, the PC-PA quadrant
concept seems not to be able to reflect disease process
in COPD patients with a follow-up up to six years. How-
ever, the already low PA and preserved PC in the “can
do, don’t do” quadrant raises the question if regularly as-
sessment of PA in clinical practice would be more sensi-
tive to detect progressive deterioration of COPD
compared to the commonly used PC.
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